Immunovant Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year	2022	2021	2020	2019	2018
Cash & Equivalents	376.53	493.82	400.15	100.57	6.99
Cash & Cash Equivalents	376.53	493.82	400.15	100.57	6.99
Cash Growth	-23.75%	23.41%	297.87%	1339.81%	-
Receivables	0.7	12.23	0.6	0	0
Other Current Assets	27.1	6.89	8.26	8.51	5.59
Total Current Assets	404.33	512.93	409.01	109.08	12.58
Property, Plant & Equipment	1.51	2.63	3.48	0.07	0.05
Other Long-Term Assets	0	0	0	0.25	1.2
Total Long-Term Assets	1.51	2.63	3.48	0.31	1.25
Total Assets	405.84	515.56	412.49	109.39	13.83
Accounts Payable	1.35	18.8	2.43	4.38	0.26
Current Debt	1.17	1.15	1.18	0	0
Other Current Liabilities	40.77	24.58	15.16	10.94	6.23
Total Current Liabilities	43.3	44.52	18.77	15.32	6.49
Long-Term Debt	0.05	1.22	2.24	0	0
Total Long-Term Liabilities	0.05	1.22	2.24	0	0
Total Liabilities	43.34	45.74	21.01	15.32	6.49
Total Debt	1.22	2.36	3.42	0	0
Debt Growth	-48.39%	-30.82%	-	-	-
Retained Earnings	-566.35	-355.39	-198.66	-91.23	-24.84
Comprehensive Income	0.85	0.4	-0.3	-0.02	0.35
Shareholders' Equity	362.49	469.83	391.48	94.07	7.34
Net Cash / Debt	375.31	491.45	396.73	100.57	6.99
Net Cash / Debt Growth	-23.63%	23.88%	294.48%	1339.81%	-
Net Cash Per Share	3.05	4.48	4.52	2.33	0.32
Working Capital	361.04	468.41	390.24	93.76	6.09
Book Value Per Share	2.94	4.28	4.46	2.18	0.33

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).